Akademik Veri Yönetim Sistemi
2nd International Congress on Medical Sciences and Biotechnology, Uşak, Türkiye, 1 - 03 Ekim 2020, ss.380
Diabetes and cancer are common human diseases that decrease life expectancy. They have
negative impact on quality of life either physiologically, psychologically, and/or socially. For
that reasons diabetes and cancer maintains popularity among researchers. Prostate cancer is a
common form of cancer in men, it constitutes 11% of all male cancers in Europe. Metformin
(1,1-dimethylbiguanide) is used in patients with type 2 diabetes. It has an established treatment
efficacy, has a good safety profile and associated with low cost. Metformin reduces insulin
resistance and fasting plasma insulin levels. Many studies showed that this drug has both in
vivo and in vitro anti-cancer activity. In the present experiment, the positive effect of metformin
on pancreas damage in diabetes and prostate cancer model was investigated. Dunning prostate
cancer model was formed in Copenhagen rat using high metastatic MAT-Lylu cells. Male
Copanhagen rats were divided into six groups: 1) Control group: %0.9 physiological saline was
received during 14 days, 2) Diabetic group: diabetes was induced after injection of 65 mg/kg
streptozotocin (STZ), 3) Cancer group: 2x104 MAT-LyLu cells were received, 4) Cancer +
metformin group: metformin was received 250 mg/kg every day following inoculation of MATLyLu cells, 5) Diabetic + cancer group: 2x104 MAT-LyLu cells were received after injection
of 65 mg/kg STZ, 6) Diabetic + cancer + metformin group: metformin was received 250 mg/kg
during experimental period, following injection of STZ and inocculation of MAT-LyLu cells.
At the end of the experiment, animals were decapitated and pancreas tissue were taken. In
diabetic, cancer and diabetic + cancer groups, total oxidant, reactive oxygen, nitric oxide, sialic
acid levels and xanthine oxidase activity were found to increase. Administration of metformin
reversed the biochemical defects in these groups. These results showed that metformin has
potential for treatment of pancreatic damage in diabetes and dunning rat prostate cancer model.